ClinicalTrials.gg
RecruitingNCT06443216Updated Jul 23, 2024

Sleep Modulation to Treat Depression

An interventional study of Auditory closed-loop stimulation and Sham stimulation in Major Depressive Disorder and Healthy, sponsored by Christoph Nissen. Recruiting at 1 site in Switzerland. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-23.

Sponsored by Christoph Nissen · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Depressive Disorder, Major with a site in Switzerland — 7 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Switzerland.

Planned enrollment
12th of 25
60 · median 60
Started
2024
with 2 others
No phase
18 of 30
6 open now
Registered
23rd of 30
by date
Lead sponsor
1 of 30
Christoph Nissen

Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, this one is the 12th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 18 with no phase, and was the 23rd registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 30 studies in Depressive Disorder, Major with a site in Switzerland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Depressive Disorder, Major with a site in Switzerland, or all of them as a file.
02

Study summary

Current first-line treatments for major depression (antidepressants and psychotherapy) show a long latency to response, and less than half of all patients experience full remission with optimized treatment, indicating the need for new developments. The aim of this study is to extend and further develop a longstanding line of research of using sleep neurophysiology as a 'window to the brain' and treatment development in major depression. Particularly, this project is designed to test the feasibility, efficacy and mechanisms of action of a new sleep-based treatment technology.

Read the detailed description

The planned study is a single-centre, doubled-blind, randomized, sham controlled, repeated measures within-subject (stimulation and sham) study including patients with major depression and healthy controls, across four sleep laboratory nights (adaptation, baseline, stimulation and sham in counterbalanced order). The investigators will test the primary hypothesis that auditory-closed loop suppression of slow wave sleep will improve depressive clinical symptomatology compared to sham stimulation.

03

Conditions studied

  • Major Depressive Disorder
  • Healthy
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • MDD according to ICD-10 criteria (F32.1/2, F33.1/2; i.e. unipolar depression) for patient group

Exclusion criteria

Exclusion Criteria:

  • Relevant psychiatric disorders (other than MDD for the patient group), such as organic psychiatric disorders, lifetime history of substance dependency or current substance abuse (smoking will be allowed for recruitment reasons), schizophrenia or other psychotic disorders, affective disorders including bipolar disorder, borderline personality disorder, autism or other severe psychiatric disorders
  • Known pregnancy
  • Unstable medical conditions, such as unstable cardiovascular or metabolic disorders, etc.
  • Relevant neurological disorders, including epilepsy, stroke, etc.
  • Organic sleep disorders including relevant sleep apnea (AHI>15/h), periodic limb movement disorder (PLMS index>5/h), Restless-Legs-Syndrome (RLS), narcolepsy, circadian rhythm disorder or shift work/ jet lag
  • Intake of medication affecting the central nervous system (other than antidepressants and lithium in patients); patients receiving benzodiazepines or (es)ketamine will not be included
  • Current brain stimulation treatment, such as electroconvulsive therapy (ECT), TMS or deep brain stimulation
  • for tDCS or TMS studies, including but not limited to metal in the head/ brain or epilepsy
  • Hearing impairment or tinnitus (auditory stimulation study)
  • Inability to follow the procedures of the study (for example due to language problems)
  • Left-handedness
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Patients with major depressive disorder according to ICD-10 criteria

    Device: Auditory closed-loop stimulation · Device: Sham stimulation

  • Experimental
    Healthy Group

    Healthy controls

    Device: Auditory closed-loop stimulation · Device: Sham stimulation

Interventions

  • DeviceAuditory closed-loop stimulation

    Auditory closed-loop suppression of slow wave sleep

  • DeviceSham stimulation

    No auditory stimulation

06

What researchers measure

Primary outcomes

  1. Montgomery Åsberg Depression Rating Scale

    Measure of the severity of depressive symptomatology The scores range between 0 to 60. The higher the score, the more symptamology of depression the subjects presents.

    Time frame: Up to three weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 24 months is below that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
Jun 5, 2024
StartActual
Jul 22, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jul 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06443216
Lead sponsor
Christoph Nissen
Responsible party
Christoph Nissen (Prof. Dr. med., University of Geneva, Switzerland) — Sponsor-investigator
First posted
Jun 5, 2024
Start date
Jul 22, 2024
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jul 23, 2024

Study contacts

Christoph Nissen, Prof. Dr. med.
Contact
christoph.nissen@hug.ch
+41.22.305.45.38

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion